Supreme Pharmaceuticals Announces Continuance to CBCA and Adoption of By-Law
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 12/22/15 -- Supreme Pharmaceuticals Inc. (the "Company") (OTC PINK: SPRWF)(CSE: SL) is pleased to announce that the Company has continued (the "Continuance") out of the jurisdiction of the Business Corporations Act (British Columbia) and into the jurisdiction of the Canada Business Corporations Act (the "CBCA") and has adopted By-Law No. 1. The Continuance took place in accordance with the annual and special meeting of shareholders held on December 18, 2015 where the shareholders of the Company approved such continuance. The Company is now a Canadian federal company.
Copies of the certificate of continuance and By- Law No. 1 have been filed under the Company's profile at .
About Supreme
Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis achieved by applying commercial agriculture practices to medical cannabis production. Supreme's flagship facility is a 342,000 sq. ft. hybrid greenhouse located in Kincardine, Ontario, which has been designed to maximize production efficiencies allowing the Company to pass savings along to its future patients.
Contacts:
Supreme Pharmaceuticals Inc.
John Fowler
(416) 630-7272
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2015 - 23:05 Uhr
Sprache: Deutsch
News-ID 441387
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 274 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Supreme Pharmaceuticals Announces Continuance to CBCA and Adoption of By-Law"
steht unter der journalistisch-redaktionellen Verantwortung von
Supreme Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
